| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 13.880 | 13.881 | 10.767 | 10.351 | 13.823 | 19.001 | 23.604 | 21.226 | 18.814 | 22.240 |
| Total Income - EUR | 13.880 | 13.881 | 10.767 | 10.351 | 14.392 | 18.443 | 31.387 | 21.226 | 18.814 | 22.251 |
| Total Expenses - EUR | 13.497 | 12.684 | 9.911 | 8.031 | 10.944 | 9.647 | 13.276 | 14.468 | 20.065 | 20.567 |
| Gross Profit/Loss - EUR | 383 | 1.196 | 855 | 2.320 | 3.448 | 8.796 | 18.111 | 6.758 | -1.251 | 1.684 |
| Net Profit/Loss - EUR | -34 | 780 | 532 | 2.010 | 3.016 | 8.281 | 17.185 | 6.279 | -1.417 | 1.050 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
Check the financial reports for the company - Dariusmed S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 6.521 | 6.988 | 5.893 | 8.131 | 5.306 | 56.866 | 49.571 | 41.709 | 34.162 | 27.090 |
| Current Assets | 11.390 | 5.475 | 7.754 | 8.510 | 14.920 | 9.357 | 13.964 | 11.824 | 19.290 | 26.901 |
| Inventories | 0 | 0 | 0 | 413 | 405 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 1.096 | 920 | 1.311 | 1.880 | 478 | 3.504 | 3.008 | 1.959 | 1.124 | 0 |
| Cash | 10.294 | 4.555 | 6.443 | 6.216 | 14.036 | 5.853 | 10.956 | 9.865 | 18.166 | 26.901 |
| Shareholders Funds | 11.008 | 12.317 | 12.641 | 14.419 | 17.156 | 25.112 | 41.740 | 48.148 | 46.585 | 47.375 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 6.903 | 145 | 1.006 | 2.222 | 3.070 | 41.111 | 21.796 | 5.386 | 6.867 | 6.617 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Dariusmed S.r.l.